1 Institute of Digestive Health and Liver Diseases, Mercy Medical Center, Baltimore, MD, 21202, USA.
2 Institute of Digestive Health and Liver Diseases, Mercy Medical Center, Baltimore, MD, 21202, USA. firstname.lastname@example.org.
3 Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA. email@example.com.
NAFLD is a spectrum of liver disease starting with fatty liver at one end of the spectrum and cirrhosis or liver cancer at the other end. Worldwide, NAFLD has become one of the most common liver diseases and it has also become one of the leading indications for liver transplantation. Our understanding of the NAFLD epidemiology, pathogenesis and its progression to cirrhosis has improved over the last 2 decades. Currently, however, there are no FDA-approved treatment options for fibrosis resulting from NAFLD. A number of compounds targeting multiple pathways involved in the progression of NAFLD are currently in phase 2-3 trials. In this review, we will briefly discuss the epidemiology, the pathogenesis and the current status of treatment of NAFLD.